ICCC
ImmuCell Corporation
NASDAQ: ICCC · HEALTHCARE · BIOTECHNOLOGY
$8.44
+1.08% today
Updated 2026-04-29
Market cap
$74.64M
P/E ratio
—
P/S ratio
2.70x
EPS (TTM)
$-0.12
Dividend yield
—
52W range
$5 – $8
Volume
0.0M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.0
Growth
C8.0
Quality
A4.0
Profitability
C6.7
Valuation
B6/9
Piotroski F-Score
Moderate
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$14.00
+65.88%
12-Month target
$4.84
-42.65%
Intrinsic (DCF)
$18.61
Margin of safety
+65.13%
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $310235.00 — positive
+ 65.13% below intrinsic value
+ Debt/equity 0.46x — low leverage
Risks
- Altman Z 1.52 — distress zone
- Thin margins at -3.76%
- Revenue declining -1.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $18.57M | $17.47M | $26.49M | $27.64M | $27.64M |
| Net income | $-2.49M | $-5.77M | $-2.16M | $-1.04M | $-2.85M |
| EPS | — | — | — | — | $-0.12 |
| Free cash flow | $-5.52M | $-6.57M | $-107822.00 | $1.22M | $310235.00 |
| Profit margin | -13.43% | -33.05% | -8.14% | -3.76% | -3.76% |
Peer comparison
Smart narrative
ImmuCell Corporation trades at $8.44. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.52, it sits in the distress. TTM revenue stands at $27.64M. with profit margins at -3.76%. Our DCF model estimates intrinsic value at $18.61.
Frequently asked questions
What is ImmuCell Corporation's stock price?
ImmuCell Corporation (ICCC) trades at $8.44.
Is ImmuCell Corporation overvalued?
Smart Value Score 22/100 (Grade F, Strong Sell). DCF value $18.61.
What is the price target of ImmuCell Corporation (ICCC)?
The analyst target price is $14.00, representing +65.9% upside from the current price of $8.44.
What is the intrinsic value of ImmuCell Corporation (ICCC)?
Based on our DCF model, intrinsic value is $18.61, a +65.1% margin of safety versus $8.44.
What is ImmuCell Corporation's revenue?
TTM revenue is $27.64M.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
1.52 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.70x
ROE-3.81%
Beta0.31
50D MA$6.77
200D MA$6.29
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—